Transport of nucleoside analogs across the plasma membrane: A clue to understanding drug-induced cytotoxicity

Current Drug Metabolism

Volumn 10, Issue 4, 2009, Pages 347-358

  Huber Ruano, I ^a   Pastor Anglada, M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antitumoral; Antiviral; CNT; ENT; Nucleoside transporter; OAT

Indexed keywords

ACICLOVIR; ADEFOVIR; CIDOFOVIR; CLADRIBINE; CLOFARABINE; CONCENTRATIVE NUCLEOSIDE TRANSPORTER; CYTARABINE; DIDANOSINE; DOXIFLURIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; FLUDARABINE; GANCICLOVIR; GEMCITABINE; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOSIDE TRANSPORTER; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER SLC22; ORGANIC CATION TRANSPORTER SLC28; ORGANIC CATION TRANSPORTER SLC29; PROBENECID; RIBAVIRIN; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

CELL MEMBRANE; CELLULAR DISTRIBUTION; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG TRANSPORT; GENETIC VARIABILITY; HUMAN; NEPHROTOXICITY; NUCLEOSIDE TRANSPORT; REVIEW; TISSUE DISTRIBUTION;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DRUG CARRIERS; EQUILIBRATIVE NUCLEOSIDE TRANSPORT PROTEINS; GENE EXPRESSION REGULATION; HUMANS; MEMBRANE TRANSPORT PROTEINS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; NUCLEOSIDE TRANSPORT PROTEINS; NUCLEOSIDES; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 68349131383     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009788499030     Document Type: Review

References (167)

1. Pastor-Anglada, M.; Cano-Soldado, P.; Molina-Arcas, M.; Lostao, M.P.; Larrayoz, I.; Martinez-Picado, J.; Casado, F.J. Cell entry and export of nucleoside analogues. Virus Res., 2005, 107(2), 151-64.
2. Ritter, C.A.; Jedlitschky, G.; Meyer zu Schwabedissen, H.; Grube, M.; Kock, K.; Kroemer, H.K. Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab. Rev., 2005, 37(1), 253-78.
3. Anzai, N.; Kanai, Y.; Endou, H. Organic anion transporter family: current knowledge. J. Pharmacol. Sci., 2006, 100(5), 411-26.
4. Robertson, E.E.; Rankin, G.O. Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion. Pharmacol. Ther., 2006, 109(3), 399-412.
5. Sekine, T.; Cha, S.H.; Endou, H. The multispecific organic anion transporter (OAT) family. Pflugers Arch., 2000, 440(3), 337-50.
6. Koepsell, H.; Endou, H. The SLC22 drug transporter family. Pflugers Arch., 2004, 447(5), 666-76.
7. Shimada, H.; Moewes, B.; Burckhardt, G. Indirect coupling to Na+ of p-aminohippuric acid uptake into rat renal basolateral membrane vesicles. Am. J. Physiol., 1987, 253(5 Pt 2), F795-801.
8. Kobayashi, Y.; Ohshiro, N.; Sakai, R.; Ohbayashi, M.; Kohyama, N.; Yamamoto, T. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J. Pharm. Pharmacol., 2005, 57(5), 573-8.
9. Sweet, D.H.; Chan, L.M.; Walden, R.; Yang, X.P.; Miller, D.S.; Pritchard, J.B. Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient. Am. J. Physiol. Renal. Physiol., 2003, 284(4), F763-9.
10. Bakhiya, A.; Bahn, A.; Burckhardt, G.; Wolff, N. Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell. Physiol. Biochem., 2003, 13(5), 249-56.
11. Ekaratanawong, S.; Anzai, N.; Jutabha, P.; Miyazaki, H.; Noshiro, R.; Takeda, M.; Kanai, Y.; Sophasan, S.; Endou, H. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J. Pharmacol. Sci., 2004, 94(3), 297-304.
12. Hasannejad, H.; Takeda, M.; Taki, K.; Shin, H.J.; Babu, E.; Jutabha, P.; Khamdang, S.; Aleboyeh, M.; Onozato, M.L.; Tojo, A.; Enomoto, A.; Anzai, N.; Narikawa, S.; Huang, X.L.; Niwa, T.; Endou, H. Interactions of human organic anion transporters with diuretics. J. Pharmacol. Exp. Ther., 2004, 308(3), 1021-9.
13. Hosoyamada, M.; Sekine, T.; Kanai, Y.; Endou, H. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol., 1999, 276(1 Pt 2), F122-8.
14. Simonson, G.D.; Vincent, A.C.; Roberg, K.J.; Huang, Y.; Iwanij, V. Molecular cloning and characterization of a novel liver-specific transport protein. J. Cell Sci., 1994, 107 (Pt 4), 1065-72.
15. Cha, S.H.; Sekine, T.; Fukushima, J.I.; Kanai, Y.; Kobayashi, Y.; Goya, T.; Endou, H. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol., 2001, 59(5), 1277-86.
16. Van Aubel, R.A.; Masereeuw, R.; Russel, F.G. Molecular pharmacology of renal organic anion transporters. Am. J. Physiol. Renal Physiol., 2000, 279(2), F216-32.
17. Koepsell, H.; Lips, K.; Volk, C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res., 2007, 24(7), 1227-51.
18. Karbach, U.; Kricke, J.; Meyer-Wentrup, F.; Gorboulev, V.; Volk, C.; Loffing-Cueni, D.; Kaissling, B.; Bachmann, S.; Koepsell, H. Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am. J. Physiol. Renal Physiol., 2000, 279(4), F679-87.
19. Choudhuri, S.; Cherrington, N.J.; Li, N.; Klaassen, C.D. Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. Drug Metab. Dispos., 2003, 31(11), 1337-45.
20. Lips, K.S.; Volk, C.; Schmitt, B.M.; Pfeil, U.; Arndt, P.; Miska, D.; Ermert, L.; Kummer, W.; Koepsell, H. Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am. J. Respir. Cell Mol. Biol., 2005, 33(1), 79-88.
21. Hayer-Zillgen, M.; Bruss, M.; Bonisch, H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br. J. Pharmacol., 2002, 136(6), 829-36.
22. Motohashi, H.; Sakurai, Y.; Saito, H.; Masuda, S.; Urakami, Y.; Goto, M.; Fukatsu, A.; Ogawa, O.; Inui, K. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol., 2002, 13(4), 866-74.
23. Al-Hasani, H.; Kunamneni, R.K.; Dawson, K.; Hinck, C.S.; Muller-Wieland, D.; Cushman, S.W. Roles of the N- and C-termini of GLUT4 in endocytosis. J. Cell Sci., 2002, 115(Pt 1), 131-40.
24. Che, M.; Ortiz, D.F.; Arias, I.M. Primary structure and functional expression of a cDNA encoding the bile canalicular, purine-specific Na(+)-nucleoside cotransporter. J. Biol. Chem., 1995, 270(23), 13596-9.
25. Huang, Q.Q.; Yao, S.Y.; Ritzel, M.W.; Paterson, A.R.; Cass, C.E.; Young, J.D. Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein. J. Biol. Chem., 1994, 269(27), 17757-60.
26. Ritzel, M.W.; Ng, A.M.; Yao, S.Y.; Graham, K.; Loewen, S.K.; Smith, K.M.; Ritzel, R.G.; Mowles, D.A.; Carpenter, P.; Chen, X.Z.; Karpinski, E.; Hyde, R.J.; Baldwin, S.A.; Cass, C.E.; Young, J.D. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J. Biol. Chem., 2001, 276(4), 2914-27.
27. Larrayoz, I.M.; Casado, F.J.; Pastor-Anglada, M.; Lostao, M.P. Electrophysiological characterization of the human Na(+)/nucleoside cotransporter 1 (hCNT1) and role of adenosine on hCNT1 function. J. Biol. Chem., 2004, 279(10), 8999-9007.
28. Konvicka, K.; Campagne, F.; Weinstein, H. Interactive construction of residue-based diagrams of proteins: the RbDe web service. Protein Eng., 2000, 13(6), 395-6.
29. Valdes, R.; Ortega, M.A.; Casado, F.J.; Felipe, A.; Gil, A.; Sanchez-Pozo, A.; Pastor-Anglada, M. Nutritional regulation of nucleoside transporter expression in rat small intestine. Gastroenterology, 2000, 119(6), 1623-30.
30. Govindarajan, R.; Bakken, A.H.; Hudkins, K.L.; Lai, Y.; Casado, F.J.; Pastor-Anglada, M.; Tse, C.M.; Hayashi, J.; Unadkat, J.D. In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 293(5), R1809-22.
31. Baldwin, S.A.; Beal, P.R.; Yao, S.Y.; King, A.E.; Cass, C.E.; Young, J.D. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch., 2004, 447(5), 735-43.
32. Gray, J.H.; Owen, R.P.; Giacomini, K.M. The concentrative nucleoside transporter family, SLC28. Pflugers Arch., 2004, 447(5), 728-34.
33. Belt, J.A. Heterogeneity of nucleoside transport in mammalian cells. Two types of transport activity in L1210 and other cultured neoplastic cells. Mol. Pharmacol., 1983, 24(3), 479-84.
34. Griffith, D.A.; Jarvis, S.M. Nucleoside and nucleobase transport systems of mammalian cells. Biochim. Biophys. Acta, 1996, 1286(3), 153-81.
35. Pennycooke, M.; Chaudary, N.; Shuralyova, I.; Zhang, Y.; Coe, I.R. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem. Biophys. Res. Commun., 2001, 280(3), 951-9.
36. Jennings, L.L.; Hao, C.; Cabrita, M.A.; Vickers, M.F.; Baldwin, S.A.; Young, J.D.; Cass, C.E. Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system. Neuropharmacology, 2001, 40(5), 722-31.
37. Griffiths, M.; Beaumont, N.; Yao, S.Y.; Sundaram, M.; Boumah, C.E.; Davies, A.; Kwong, F.Y.; Coe, I.; Cass, C.E.; Young, J.D.; Baldwin, S.A. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat. Med., 1997, 3(1), 89-93.
38. Baldwin, S.A.; Yao, S.Y.; Hyde, R.J.; Ng, A.M.; Foppolo, S.; Barnes, K.; Ritzel, M.W.; Cass, C.E.; Young, J.D. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J. Biol. Chem., 2005, 280(16), 15880-7.
39. Govindarajan, R.; Leung, G.P.; Zhou, M.; Tse, C.M.; Wang, J.; Unadkat, J.D. Facilitated Mitochondrial Import of Anti-viral and Anti-cancer Nucleoside Drugs by Human Equilibrative Nucleoside Transporter-3 (hENT3). Am. J. Physiol. Gastrointest. Liver Physiol, 2009.
40. Molho-Pessach, V.; Lerer, I.; Abeliovich, D.; Agha, Z.; Abu Libdeh, A.; Broshtilova, V.; Elpeleg, O.; Zlotogorski, A. The H syndrome is caused by mutations in the nucleoside transporter hENT3. Am. J. Hum. Genet., 2008, 83(4), 529-34.
41. Kong, W.; Engel, K.; Wang, J. Mammalian nucleoside transporters. Curr. Drug Metab., 2004, 5(1), 63-84.
42. Barnes, K.; Dobrzynski, H.; Foppolo, S.; Beal, P.R.; Ismat, F.; Scullion, E.R.; Sun, L.; Tellez, J.; Ritzel, M.W.; Claycomb, W.C.; Cass, C.E.; Young, J.D.; Billeter-Clark, R.; Boyett, M.R.; Baldwin, S.A. Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ. Res., 2006, 99(5), 510-9.
43. Roden, M.; Paterson, A.R.; Turnheim, K. Sodium-dependent nucleoside transport in rabbit intestinal epithelium. Gastroenterology, 1991, 100(6), 1553-62.
44. Errasti-Murugarren, E.; Pastor-Anglada, M.; Casado, F.J. Role of CNT3 in the transepithelial flux of nucleosides and nucleoside-derived drugs. J. Physiol., 2007, 582(Pt 3), 1249-60.
45. Aymerich, I.; Foufelle, F.; Ferre, P.; Casado, F.J.; Pastor-Anglada, M. Extracellular adenosine activates AMP-dependent protein kinase (AMPK). J. Cell Sci., 2006, 119(Pt 8), 1612-21.
46. Duflot, S.; Riera, B.; Fernandez-Veledo, S.; Casado, V.; Norman, R.I.; Casado, F.J.; Lluis, C.; Franco, R.; Pastor-Anglada, M. ATP-sensitive K(+) channels regulate the concentrative adenosine transporter CNT2 following activation by A(1) adenosine receptors. Mol. Cell. Biol., 2004, 24(7), 2710-9.
47. Fernandez-Veledo, S.; Huber-Ruano, I.; Aymerich, I.; Duflot, S.; Casado, F.J.; Pastor-Anglada, M. Bile acids alter the subcellular localization of CNT2 (concentrative nucleoside cotransporter) and increase CNT2-related transport activity in liver parenchymal cells. Biochem. J., 2006, 395(2), 337-44.
48. Klein, K.; Kullak-Ublick, G.A.; Wagner, M.; Trauner, M.; Eloranta, J.J. Hepatocyte nuclear factor-4{alpha} and bile acids regulate human concentrative nucleoside transporter-1 gene expression. Am. J. Physiol. Gastrointest. Liver Physiol., 2009.
49. Meester, B.J.; Shankley, N.P.; Welsh, N.J.; Meijler, F.L.; Black, J.W. Pharmacological analysis of the activity of the adenosine uptake inhibitor, dipyridamole, on the sinoatrial and atrioventricular nodes of the guinea-pig. Br. J. Pharmacol., 1998, 124(4), 729-41.
50. Ackley, M.A.; Governo, R.J.; Cass, C.E.; Young, J.D.; Baldwin, S.A.; King, A.E. Control of glutamatergic neurotransmission in the rat spinal dorsal horn by the nucleoside transporter ENT1. J. Physiol., 2003, 548(Pt 2), 507-17.
51. Soler, C.; Garcia-Manteiga, J.; Valdes, R.; Xaus, J.; Comalada, M.; Casado, F.J.; Pastor-Anglada, M.; Celada, A.; Felipe, A. Macrophages require different nucleoside transport systems for proliferation and activation. FASEB J., 2001, 15(11), 1979-88.
52. Gomez-Angelats, M.; del Santo, B.; Mercader, J.; Ferrer-Martinez, A.; Felipe, A.; Casado, J.; Pastor-Anglada, M. Hormonal regulation of concentrative nucleoside transport in liver parenchymal cells. Biochem. J. 1996, 313 (Pt 3), 915-20.
53. Podgorska, M.; Kocbuch, K.; Grden, M.; Szulc, A.; Szutowicz, A.; Pawelczyk, T. Different signaling pathways utilized by insulin to regulate the expression of ENT2, CNT1, CNT2 nucleoside transporters in rat cardiac fibroblasts. Arch. Biochem. Biophys., 2007, 464(2), 344-9.
54. Fideu, M.D.; Miras-Portugal, M.T. Long term regulation of nucleoside transport by thyroid hormone (T3) in cultured chromaffin cells. Neurochem. Res., 1992, 17(11), 1099-104.
55. Lu, R.; Chan, B.S.; Schuster, V.L. Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am. J. Physiol. 1999, 276(2 Pt 2), F295-303.
56. Terlouw, S.A.; Masereeuw, R.; Russel, F.G. Modulatory effects of hormones, drugs, and toxic events on renal organic anion transport. Biochem. Pharmacol., 2003, 65(9), 1393-405.
57. Barros, S.A.; Srimaroeng, C.; Perry, J.L.; Walden, R.; Dembla-Rajpal, N.; Sweet, D.H.; Pritchard, J.B. Activation of Protein Kinase C{zeta} Increases OAT1 (SLC22A6)- and OAT3 (SLC22A8)-mediated Transport. J. Biol. Chem., 2009, 284(5), 2672-9.
58. Sauvant, C.; Holzinger, H.; Gekle, M. Modulation of the basolateral and apical step of transepithelial organic anion secretion in proximal tubular opossum kidney cells. Acute effects of epidermal growth factor and mitogen-activated protein kinase. J. Biol. Chem., 2001, 276(18), 14695-703.
59. Sauvant, C.; Hesse, D.; Holzinger, H.; Evans, K.K.; Dantzler, W.H.; Gekle, M. Action of EGF and PGE2 on basolateral organic anion uptake in rabbit proximal renal tubules and hOAT1 expressed in human kidney epithelial cells. Am. J. Physiol. Renal Physiol., 2004, 286(4), F774-83.
60. Halpin, P.A.; Renfro, J.L. Renal organic anion secretion: evidence for dopaminergic and adrenergic regulation. Am. J. Physiol. 1996, 271(5 Pt 2), R1372-9.
61. Jensen, R.E.; Berndt, W.O. Epinephrine and norepinephrine enhance p-aminohippurate transport into basolateral membrane vesicles. J. Pharmacol. Exp. Ther., 1988, 244(2), 543-9.
62. Schoemaker, M.H.; Conde de la Rosa, L.; Buist-Homan, M.; Vrenken, T.E.; Havinga, R.; Poelstra, K.; Haisma, H.J.; Jansen, P.L.; Moshage, H. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology, 2004, 39(6), 1563-73.
63. Ljubojevic, M.; Balen, D.; Breljak, D.; Kusan, M.; Anzai, N.; Bahn, A.; Burckhardt, G.; Sabolic, I. Renal expression of organic anion transporter OAT2 in rats and mice is regulated by sex hormones. Am. J. Physiol. Renal Physiol., 2007, 292(1), F361-72.
64. Ciarimboli, G.; Struwe, K.; Arndt, P.; Gorboulev, V.; Koepsell, H.; Schlatter, E.; Hirsch, J.R. Regulation of the human organic cation transporter hOCT1. J. Cell. Physiol., 2004, 201(3), 420-8.
65. Cetinkaya, I.; Ciarimboli, G.; Yalcinkaya, G.; Mehrens, T.; Velic, A.; Hirsch, J.R.; Gorboulev, V.; Koepsell, H.; Schlatter, E. Regulation of human organic cation transporter hOCT2 by PKA, PI3K, and calmodulin-dependent kinases. Am. J. Physiol. Renal Physiol., 2003, 284(2), F293-302.
66. Martel, F.; Keating, E.; Calhau, C.; Grundemann, D.; Schomig, E.; Azevedo, I. Regulation of human extraneuronal monoamine transporter (hEMT) expressed in HEK293 cells by intracellular second messenger systems. Naunyn. Schmiedebergs Arch. Pharmacol., 2001, 364(6), 487-95.
67. Saborowski, M.; Kullak-Ublick, G.A.; Eloranta, J.J. The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha. J. Pharmacol. Exp. Ther., 2006, 317(2), 778-85.
68. Popowski, K.; Eloranta, J.J.; Saborowski, M.; Fried, M.; Meier, P.J.; Kullak-Ublick, G.A. The human organic anion transporter 2 gene is transactivated by hepatocyte nuclear factor-4 alpha and suppressed by bile acids. Mol. Pharmacol., 2005, 67(5), 1629-38.
69. Asaka, J.; Terada, T.; Okuda, M.; Katsura, T.; Inui, K. Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3. Pharm. Res., 2006, 23(4), 697-704.
70. Urakami, Y.; Okuda, M.; Saito, H.; Inui, K. Hormonal regulation of organic cation transporter OCT2 expression in rat kidney. FEBS Lett., 2000, 473(2), 173-6.
71. Casanello, P.; Torres, A.; Sanhueza, F.; Gonzalez, M.; Farias, M.; Gallardo, V.; Pastor-Anglada, M.; San Martin, R.; Sobrevia, L. Equilibrative nucleoside transporter 1 expression is downregulated by hypoxia in human umbilical vein endothelium. Circ. Res., 2005, 97(1), 16-24.
72. Puebla, C.; Farias, M.; Gonzalez, M.; Vecchiola, A.; Aguayo, C.; Krause, B.; Pastor-Anglada, M.; Casanello, P.; Sobrevia, L. High D-glucose reduces SLC29A1 promoter activity and adenosine transport involving specific protein 1 in human umbilical vein endothelium. J. Cell. Physiol., 2008, 215(3), 645-56.
73. Aguayo, C.; Casado, J.; Gonzalez, M.; Pearson, J.D.; Martin, R.S.; Casanello, P.; Pastor-Anglada, M.; Sobrevia, L. Equilibrative nucleoside transporter 2 is expressed in human umbilical vein endothelium, but is not involved in the inhibition of adenosine transport induced by hyperglycaemia. Placenta, 2005, 26(8-9), 641-53.
74. Pawelczyk, T.; Podgorska, M.; Sakowicz, M. The effect of insulin on expression level of nucleoside transporters in diabetic rats. Mol. Pharmacol., 2003, 63(1), 81-8.
75. Guillen-Gomez, E.; Calbet, M.; Casado, J.; de Lecea, L.; Soriano, E.; Pastor-Anglada, M.; Burgaya, F. Distribution of CNT2 and ENT1 transcripts in rat brain: selective decrease of CNT2 mRNA in the cerebral cortex of sleep-deprived rats. J. Neurochem., 2004, 90(4), 883-93.
76. Ahn, S.Y.; Bhatnagar, V. Update on the molecular physiology of organic anion transporters. Curr. Opin. Nephrol. Hypertens., 2008, 17(5), 499-505.
77. Thomas, M.C.; Tikellis, C.; Burns, W.C.; Thallas, V.; Forbes, J.M.; Cao, Z.; Osicka, T.M.; Russo, L.M.; Jerums, G.; Ghabrial, H.; Cooper, M.E.; Kantharidis, P. Reduced tubular cation transport in diabetes: prevented by ACE inhibition. Kidney Int., 2003, 63(6), 2152-61.
78. Thomas, M.C.; Tikellis, C.; Kantharidis, P.; Burns, W.C.; Cooper, M.E.; Forbes, J.M. The role of advanced glycation in reduced organic cation transport associated with experimental diabetes. J. Pharmacol. Exp. Ther., 2004, 311(2), 456-66.
79. Habu, Y.; Yano, I.; Takeuchi, A.; Saito, H.; Okuda, M.; Fukatsu, A.; Inui, K. Decreased activity of basolateral organic ion transports in hyperuricemic rat kidney: roles of organic ion transporters, rOAT1, rOAT3 and rOCT2. Biochem. Pharmacol., 2003, 66(6), 1107-14.
80. Denk, G.U.; Soroka, C.J.; Mennone, A.; Koepsell, H.; Beuers, U.; Boyer, J.L. Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatology, 2004, 39(5), 1382-9.
81. Dragan, Y.; Valdes, R.; Gomez-Angelats, M.; Felipe, A.; Javier Casado, F.; Pitot, H.; Pastor-Anglada, M. Selective loss of nucleoside carrier expression in rat hepatocarcinomas. Hepatology, 2000, 32(2), 239-46.
82. Mackey, J.R.; Mani, R.S.; Selner, M.; Mowles, D.; Young, J.D.; Belt, J.A.; Crawford, C.R.; Cass, C.E. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res., 1998, 58(19), 4349-57.
83. Mackey, J.R.; Jennings, L.L.; Clarke, M.L.; Santos, C.L.; Dabbagh, L.; Vsianska, M.; Koski, S.L.; Coupland, R.W.; Baldwin, S.A.; Young, J.D.; Cass, C.E. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin. Cancer Res., 2002, 8(1), 110-6.
84. Lai, R.; Bartlett, N.L.; Mackey, J.R.; Jung, S.H.; Johnson, J.L.; Cook, J.R.; Jones, D.; Cass, C.E.; Young, J.D.; Said, J.; Cheson, B.; Hsi, E.D. High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/ refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - A CALGB 59804 correlative study. Leuk. Lymphoma, 2008, 49(6), 1202-5.
85. King, K.M.; Damaraju, V.L.; Vickers, M.F.; Yao, S.Y.; Lang, T.; Tackaberry, T.E.; Mowles, D.A.; Ng, A.M.; Young, J.D.; Cass, C.E. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol. Pharmacol., 2006, 69(1), 346-53.
86. Cano-Soldado, P.; Lorrayoz, I.M.; Molina-Arcas, M.; Casado, F.J.; Martinez-Picado, J.; Lostao, M.P.; Pastor-Anglada, M. Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1). Antivir. Ther., 2004, 9(6), 993-1002.
87. Cihlar, T.; Lin, D.C.; Pritchard, J.B.; Fuller, M.D.; Mendel, D.B.; Sweet, D.H. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol. Pharmacol., 1999, 56(3), 570-80.
88. Ward, J.L.; Sherali, A.; Mo, Z.P.; Tse, C.M. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. Ent2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J. Biol. Chem., 2000, 275(12), 8375-81.
89. Ritzel, M.W.; Yao, S.Y.; Huang, M.Y.; Elliott, J.F.; Cass, C.E.; Young, J.D. Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1). Am. J. Physiol., 1997, 272(2 Pt 1), C707-14.
90. Uwai, Y.; Ida, H.; Tsuji, Y.; Katsura, T.; Inui, K. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm. Res., 2007, 24(4), 811-5.
91. Truong, D.M.; Kaler, G.; Khandelwal, A.; Swaan, P.W.; Nigam, S.K. Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discrimination. J. Biol. Chem., 2008, 283(13), 8654-63.
92. Holland, J.J.; Domingo, E.; de la Torre, J.C.; Steinhauer, D.A. Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J. Virol., 1990, 64(8), 3960-2.
93. Crotty, S.; Maag, D.; Arnold, J.J.; Zhong, W.; Lau, J.Y.; Hong, Z.; Andino, R.; Cameron, C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med., 2000, 6(12), 1375-9.
94. Crotty, S.; Cameron, C.E.; Andino, R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. USA, 2001, 98(12), 6895-900.
95. Grande-Perez, A.; Sierra, S.; Castro, M.G.; Domingo, E.; Lowenstein, P.R. Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc. Natl. Acad. Sci. USA, 2002, 99(20), 12938-43.
96. Loeb, L.A.; Essigmann, J.M.; Kazazi, F.; Zhang, J.; Rose, K.D.; Mullins, J.I. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl. Acad. Sci. USA, 1999, 96(4), 1492-7.
97. Loeb, L.A.; Mullins, J.I. Lethal mutagenesis of HIV by mutagenic ribonucleoside analogs. AIDS Res. Hum. Retroviruses, 2000, 16(1), 1-3.
98. Sierra, S.; Davila, M.; Lowenstein, P.R.; Domingo, E. Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J. Virol., 2000, 74(18), 8316-23.
99. Galmarini, C.M.; Mackey, J.R.; Dumontet, C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia, 2001, 15(6), 875-90.
100. Zhang, J.; Visser, F.; King, K.M.; Baldwin, S.A.; Young, J.D.; Cass, C.E. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev., 2007, 26(1), 85-110.
101. Nagai, K.; Nagasawa, K.; Kihara, Y.; Okuda, H.; Fujimoto, S. Anticancer nucleobase analogues 6-mercaptopurine and 6-thioguanine are novel substrates for equilibrative nucleoside transporter 2. Int. J. Pharm., 2007, 333(1-2), 56-61.
102. Ritzel, M.W.; Ng, A.M.; Yao, S.Y.; Graham, K.; Loewen, S.K.; Smith, K.M.; Hyde, R.J.; Karpinski, E.; Cass, C.E.; Baldwin, S.A.; Young, J.D. Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Mol. Membr. Biol., 2001, 18(1), 65-72.
103. Yao, S.Y.; Ng, A.M.; Vickers, M.F.; Sundaram, M.; Cass, C.E.; Baldwin, S.A.; Young, J.D. Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2. Chimeric constructs reveal a role for the ENT2 helix 5-6 region in nucleobase translocation. J. Biol. Chem., 2002, 277(28), 24938-48.
104. Yoshida, S.; Matsukage, A.; Koike, K. [Molecular mechanisms for replication and repair of DNA (author's transl)]. Tanpakushitsu Kakusan Koso, 1979, 24(8), 1054-62.
105. Smith, C.L.; Pilarski, L.M.; Egerton, M.L.; Wiley, J.S. Nucleoside transport and proliferative rate in human thymocytes and lymphocytes. Blood, 1989, 74(6), 2038-42.
106. Gati, W.P.; Paterson, A.R.; Larratt, L.M.; Turner, A.R.; Belch, A.R. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood, 1997, 90(1), 346-53.
107. Gati, W.P.; Paterson, A.R.; Belch, A.R.; Chlumecky, V.; Larratt, L.M.; Mant, M.J.; Turner, A.R. Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC). Leuk. Lymphoma, 1998, 32(1-2), 45-54.
108. Raza, A.; Gezer, S.; Anderson, J.; Lykins, J.; Bennett, J.; Browman, G.; Goldberg, J.; Larson, R.; Vogler, R.; Preisler, H.D. Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study. Exp. Hematol., 1992, 20(10), 1194-200.
109. Molina-Arcas, M.; Moreno-Bueno, G.; Cano-Soldado, P.; Hernandez-Vargas, H.; Casado, F.J.; Palacios, J.; Pastor-Anglada, M. Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5′-DFUR in breast cancer MCF7 cells. Biochem. Pharmacol., 2006, 72(12), 1646-56.
110. Cano-Soldado, P.; Molina-Arcas, M.; Alguero, B.; Larrayoz, I.; Lostao, M.P.; Grandas, A.; Casado, F.J.; Pastor-Anglada, M. Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells. Biochem. Pharmacol., 2008, 75(3), 639-48.
111. Nishioka, M.; Miyamoto, H.; Kurita, N.; Higashijima, J.; Yoshikawa, K.; Miyatani, T.; Shimada, M. Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer. Hepatogastroenterology, 2007, 54(76), 1089-93.
112. Osato, D.H.; Huang, C.C.; Kawamoto, M.; Johns, S.J.; Stryke, D.; Wang, J.; Ferrin, T.E.; Herskowitz, I.; Giacomini, K.M. Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics, 2003, 13(5), 297-301.
113. Owen, R.P.; Lagpacan, L.L.; Taylor, T.R.; De La Cruz, M.; Huang, C.C.; Kawamoto, M.; Johns, S.J.; Stryke, D.; Ferrin, T.E.; Giacomini, K.M. Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2. Drug Metab. Dispos., 2006, 34(1), 12-5.
114. Damaraju, S.; Zhang, J.; Visser, F.; Tackaberry, T.; Dufour, J.; Smith, K.M.; Slugoski, M.; Ritzel, M.W.; Baldwin, S.A.; Young, J.D.; Cass, C.E. Identification and functional characterization of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), arising from single nucleotide polymorphisms in coding regions of the hCNT3 gene. Pharmacogenet. Genomics, 2005, 15(3), 173-82.
115. Kim, S.R.; Saito, Y.; Maekawa, K.; Sugiyama, E.; Kaniwa, N.; Ueno, H.; Okusaka, T.; Morizane, C.; Yamamoto, N.; Ikeda, M.; Yoshida, T.; Minami, H.; Furuse, J.; Ishii, H.; Saijo, N.; Kamatani, N.; Ozawa, S.; Sawada, J. Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). Drug Metab. Pharmacokinet., 2006, 21(3), 248-56.
116. Myers, S.N.; Goyal, R.K.; Roy, J.D.; Fairfull, L.D.; Wilson, J.W.; Ferrell, R.E. Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet. Genomics, 2006, 16(5), 315-20.
117. Badagnani, I.; Chan, W.; Castro, R.A.; Brett, C.M.; Huang, C.C.; Stryke, D.; Kawamoto, M.; Johns, S.J.; Ferrin, T.E.; Carlson, E.J.; Burchard, E.G.; Giacomini, K.M. Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenom. J., 2005, 5(3), 157-65.
118. Urban, T.J.; Sebro, R.; Hurowitz, E.H.; Leabman, M.K.; Badagnani, I.; Lagpacan, L.L.; Risch, N.; Giacomini, K.M. Functional genomics of membrane transporters in human populations. Genome. Res., 2006, 16(2), 223-30.
119. Owen, R.P.; Gray, J.H.; Taylor, T.R.; Carlson, E.J.; Huang, C.C.; Kawamoto, M.; Johns, S.J.; Stryke, D.; Ferrin, T.E.; Giacomini, K.M. Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2. Pharmacogenet. Genomics, 2005, 15(2), 83-90.
120. Bleasby, K.; Hall, L.A.; Perry, J.L.; Mohrenweiser, H.W.; Pritchard, J.B. Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6). J. Pharmacol. Exp. Ther., 2005, 314(2), 923-31.
121. Ogasawara, K.; Terada, T.; Motohashi, H.; Asaka, J.; Aoki, M.; Katsura, T.; Kamba, T.; Ogawa, O.; Inui, K. Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. J. Hum. Genet., 2008, 53(7), 607-14.
122. Yee, S.W.; Shima, J.E.; Hesselson, S.; Nguyen, L.; De Val, S.; Lafond, R.J.; Kawamoto, M.; Johns, S.J.; Stryke, D.; Kwok, P.Y.; Ferrin, T.E.; Black, B.L.; Gurwitz, D.; Ahituv, N.; Giacomini, K.M. Identification and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2). J. Pharmacol. Exp. Ther., 2009, 328(3), 699-707.
123. Kerb, R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett., 2006, 234(1), 4-33.
124. Errasti-Murugarren, E.; Cano-Soldado, P.; Pastor-Anglada, M.; Casado, F.J. Functional characterization of a nucleoside-derived drug transporter variant (hCNT3C602R) showing altered sodiumbinding capacity. Mol. Pharmacol., 2008, 73(2), 379-86.
125. Shu, Y.; Brown, C.; Castro, R.A.; Shi, R.J.; Lin, E.T.; Owen, R.P.; Sheardown, S.A.; Yue, L.; Burchard, E.G.; Brett, C.M.; Giacomini, K.M. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther., 2008, 83(2), 273-80.
126. Vasile, E.; Giovannetti, E.; Tibaldi, C.; Mey, V.; Nannizzi, S.; Landi, L.; Stasi, I.; Danesi, R.; Del Tacca, M.; Falcone, A. Analysis of single nucleotide polymorphisms (SNPs) of cytidine deaminase (CDA) and xeroma pigmentosum group D (XPD) genes for the prediction of clinical response to gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) patients. J. Clin. Oncol. (Meeting Abstracts), 2006, 24, 7219.
127. Kwon, W.S.; Rha, S.Y.; Choi, Y.H.; Lee, J.O.; Park, K.H.; Jung, J.J.; Kim, T.S.; Jeung, H.C.; Chung, H.C. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet. Genomics, 2006, 16(6), 429-38.
128. del Santo, B.; Valdes, R.; Mata, J.; Felipe, A.; Casado, F.J.; Pastor-Anglada, M. Differential expression and regulation of nucleoside transport systems in rat liver parenchymal and hepatoma cells. Hepatology, 1998, 28(6), 1504-11.
129. Cass, C.E.; King, K.M.; Montano, J.T.; Janowska-Wieczorek, A. A comparison of the abilities of nitrobenzylthioinosine, dilazep, and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin). Cancer Res., 1992, 52(21), 5879-86.
130. Pastor-Anglada, M.; Molina-Arcas, M.; Casado, F.J.; Bellosillo, B.; Colomer, D.; Gil, J. Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia, 2004, 18(3), 385-93.
131. Mori, R.; Ishikawa, T.; Ichikawa, Y.; Taniguchi, K.; Matsuyama, R.; Ueda, M.; Fujii, Y.; Endo, I.; Togo, S.; Danenberg, P.V.; Shimada, H. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol. Rep., 2007, 17(5), 1201-5.
132. Giovannetti, E.; Del Tacca, M.; Mey, V.; Funel, N.; Nannizzi, S.; Ricci, S.; Orlandini, C.; Boggi, U.; Campani, D.; Del Chiaro, M.; Iannopollo, M.; Bevilacqua, G.; Mosca, F.; Danesi, R. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res., 2006, 66(7), 3928-35.
133. Spratlin, J.; Sangha, R.; Glubrecht, D.; Dabbagh, L.; Young, J.D.; Dumontet, C.; Cass, C.; Lai, R.; Mackey, J.R. The absence of human
134. Oguri, T.; Achiwa, H.; Muramatsu, H.; Ozasa, H.; Sato, S.; Shimizu, S.; Yamazaki, H.; Eimoto, T.; Ueda, R. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett., 2007, 256(1), 112-9.
135. Santini, D.; Perrone, G.; Vincenzi, B.; Lai, R.; Cass, C.; Alloni, R.; Rabitti, C.; Antinori, A.; Vecchio, F.; Morini, S.; Magistrelli, P.; Coppola, R.; Mackey, J.R.; Tonini, G. Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer. Ann. Oncol., 2008, 19(4), 724-8.
136. Molina-Arcas, M.; Bellosillo, B.; Casado, F.J.; Montserrat, E.; Gil, J.; Colomer, D.; Pastor-Anglada, M. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood, 2003, 101(6), 2328-34.
137. Molina-Arcas, M.; Marce, S.; Villamor, N.; Huber-Ruano, I.; Casado, F.J.; Bellosillo, B.; Montserrat, E.; Gil, J.; Colomer, D.; Pastor-Anglada, M. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia, 2005, 19(1), 64-8.
138. Peng, X.X.; Shi, Z.; Damaraju, V.L.; Huang, X.C.; Kruh, G.D.; Wu, H.C.; Zhou, Y.; Tiwari, A.; Fu, L.; Cass, C.E.; Chen, Z.S. Upregulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leuk. Res., 2008, 32(5), 799-809.
139. Stam, R.W.; den Boer, M.L.; Meijerink, J.P.; Ebus, M.E.; Peters, G.J.; Noordhuis, P.; Janka-Schaub, G.E.; Armstrong, S.A.; Korsmeyer, S.J.; Pieters, R. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood, 2003, 101(4), 1270-6.
140. Marce, S.; Molina-Arcas, M.; Villamor, N.; Casado, F.J.; Campo, E.; Pastor-Anglada, M.; Colomer, D. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica, 2006, 91(7), 895-902.
141. Richel, D.J.; Colly, L.P.; Arkesteijn, G.J.; Arentsen-Honders, M.W.; Kerster, M.G.; ter Riet, P.M.; Willemze, R. Substrate-specific deoxycytidine kinase deficiency in 1-beta-D-arabinofuranosylcytosine-resistant leukemic cells. Cancer Res., 1990, 50(20), 6515-9.
142. Bergman, A.M.; Pinedo, H.M.; Jongsma, A.P.; Brouwer, M.; Ruiz van Haperen, V.W.; Veerman, G.; Leyva, A.; Eriksson, S.; Peters, G.J. Decreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem. Pharmacol., 1999, 57(4), 397-406.
143. Giovannetti, E.; Mey, V.; Loni, L.; Nannizzi, S.; Barsanti, G.; Savarino, G.; Ricciardi, S.; Del Tacca, M.; Danesi, R. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. Pharmacol. Res., 2007, 55(4), 343-9.
144. Hubeek, I.; Stam, R.W.; Peters, G.J.; Broekhuizen, R.; Meijerink, J.P.; van Wering, E.R.; Gibson, B.E.; Creutzig, U.; Zwaan, C.M.; Cloos, J.; Kuik, D.J.; Pieters, R.; Kaspers, G.J. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br. J. Cancer, 2005, 93(12), 1388-94.
145. Eisele, L.; Klein-Hitpass, L.; Chatzimanolis, N.; Opalka, B.; Boes, T.; Seeber, S.; Moritz, T.; Flasshove, M. Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia. Acta Haematol., 2007, 117(1), 8-15.
146. Galmarini, C.M.; Thomas, X.; Graham, K.; El Jafaari, A.; Cros, E.; Jordheim, L.; Mackey, J.R.; Dumontet, C. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br. J. Haematol., 2003, 122(1), 53-60.
147. Sarkar, M.; Han, T.; Damaraju, V.; Carpenter, P.; Cass, C.E.; Agarwal, R.P. Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells. Biochem. Pharmacol., 2005, 70(3), 426-32.
148. Tsujie, M.; Nakamori, S.; Nakahira, S.; Takahashi, Y.; Hayashi, N.; Okami, J.; Nagano, H.; Dono, K.; Umeshita, K.; Sakon, M.; Monden, M. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res., 2007, 27(4B), 2241-9.
149. Farre, X.; Guillen-Gomez, E.; Sanchez, L.; Hardisson, D.; Plaza, Y.; Lloberas, J.; Casado, F.J.; Palacios, J.; Pastor-Anglada, M. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int. J. Cancer, 2004, 112(6), 959-66.
150. Gloeckner-Hofmann, K.; Guillen-Gomez, E.; Schmidtgen, C.; Porstmann, R.; Ziegler, R.; Stoss, O.; Casado, F.J.; Ruschoff, J.; Pastor-Anglada, M. Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer. Oncology, 2006, 70(3), 238-44.
151. Tsang, R.Y.; Santos, C.; Ghosh, S.; Dabbagh, L.; King, K.; Young, J.; Cass, C.E.; Mackey, J.R.; Lai, R. Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia. Mod. Pathol., 2008.
152. Purcet, S.; Minuesa, G.; Molina-Arcas, M.; Erkizia, I.; Casado, F.J.; Clotet, B.; Martinez-Picado, J.; Pastor-Anglada, M. 3′-Azido-2′,3′-dideoxythymidine (zidovudine) uptake mechanisms in T lymphocytes. Antivir. Ther., 2006, 11(6), 803-11.
153. Minuesa, G.; Volk, C.; Molina-Arcas, M.; Gorboulev, V.; Erkizia, I.; Arndt, P.; Clotet, B.; Pastor-Anglada, M.; Koepsell, H.; Martinez-Picado, J. Transport of Lamivudine (3TC) and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors With Human Organic Cation Transporters 1, 2, and 3. J. Pharmacol. Exp. Ther., 2009.
154. Nakai, K.; Tanaka, H.; Hanada, K.; Ogata, H.; Suzuki, F.; Kumada, H.; Miyajima, A.; Ishida, S.; Sunouchi, M.; Habano, W.; Kamikawa, Y.; Kubota, K.; Kita, J.; Ozawa, S.; Ohno, Y. Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab. Dispos., 2008, 36(9), 1786-93.
155. Lacy, S.A.; Hitchcock, M.J.; Lee, W.A.; Tellier, P.; Cundy, K.C. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol. Sci., 1998, 44(2), 97-106.
156. Ho, E.S.; Lin, D.C.; Mendel, D.B.; Cihlar, T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol., 2000, 11(3), 383-93.
157. Patil, S.D.; Ngo, L.Y.; Glue, P.; Unadkat, J.D. Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter. Pharm. Res., 1998, 15(6), 950-2.
158. Mangia, A.; Ricci, G.L.; Persico, M.; Minerva, N.; Carretta, V.; Bacca, D.; Cela, M.; Piattelli, M.; Annese, M.; Maio, G.; Conte, D.; Guadagnino, V.; Pazienza, V.; Festi, D.; Spirito, F.; Andriulli, A. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J. Viral Hepatol., 2005, 12(3), 292-9.
159. Ljubuncic, P.; Konikoff, F.M.; Blendis, L.M.; Bomzon, A. Effect of interferon, ribavirin and ursodeoxycholic acid in patients with hepatitis C infection. Hepatogastroenterology, 2005, 52(64), 1191-6.
160. Azzaroli, F.; Accogli, E.; Nigro, G.; Trere, D.; Giovanelli, S.; Miracolo, A.; Lodato, F.; Montagnani, M.; Tame, M.; Colecchia, A.; Mwangemi, C.; Festi, D.; Roda, E.; Derenzini, M.; Mazzella, G. Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. World J. Gastroenterol., 2004, 10(21), 3099-102.
161. Panayiotidis, P.; Ganeshaguru, K.; Jabbar, S.A.; Hoffbrand, A.V. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br. J. Haematol., 1993, 85(3), 439-45.
162. Kay, N.E.; Han, L.; Bone, N.; Williams, G. Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis. Br. J. Haematol., 2001, 112(3), 760-7.
163. Fernandez Calotti, P.; Galmarini, C.M.; Canones, C.; Gamberale, R.; Saenz, D.; Avalos, J.S.; Chianelli, M.; Rosenstein, R.; Giordano, M. Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia. Biochem. Pharmacol., 2008, 75(4), 857-65.
164. Beck, F.W.; Eilender, D.S.; Dandashi, M.H.; Siddiq, F.; Snell, D.C.; Godmere, M.A.; Al-Katib, A.M.; Mohammad, R.M. Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia. Int. J. Mol. Med., 2004, 14(1), 113-9.
165. Mohammad, R.M.; Beck, F.W.; Katato, K.; Hamdy, N.; Wall, N.; Al-Katib, A. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5′-NT and Bax/Bcl-2. Biol. Chem., 1998, 379(10), 1253-61.
166. Mohammad, R.M.; Limvarapuss, C.; Hamdy, N.; Dutcher, B.S.; Beck, F.W.; Wall, N.R.; Al-Katib, A.M. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine. Int. J. Oncol., 1999, 14(5), 945-50.
167. El-Rayes, B.F.; Gadgeel, S.; Shields, A.F.; Manza, S.; Lorusso, P.; Philip, P.A. Phase I study of bryostatin 1 and gemcitabine. Clin. Cancer Res., 2006, 12(23), 7059-62.